156 related articles for article (PubMed ID: 31267380)
1. T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting.
Sun X; Yu Y; Ma L; Xue X; Gao Z; Ma J; Zhang M
Invest New Drugs; 2020 Jun; 38(3):722-732. PubMed ID: 31267380
[TBL] [Abstract][Full Text] [Related]
2. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
[TBL] [Abstract][Full Text] [Related]
3. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
[TBL] [Abstract][Full Text] [Related]
4. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
[TBL] [Abstract][Full Text] [Related]
5. B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells.
Sun X; Zhao J; Ma L; Sun X; Ge J; Yu Y; Ma J; Zhang M
Invest New Drugs; 2021 Feb; 39(1):24-33. PubMed ID: 32770284
[TBL] [Abstract][Full Text] [Related]
6. Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies.
Ma L; Ma J; Sun X; Liu H
Invest New Drugs; 2023 Jun; 41(3):522-531. PubMed ID: 37198354
[TBL] [Abstract][Full Text] [Related]
7. The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer.
Zhao H; Ma J; Lei T; Ma W; Zhang M
Invest New Drugs; 2019 Oct; 37(5):810-817. PubMed ID: 30374653
[TBL] [Abstract][Full Text] [Related]
8. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
10. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
11. [Expression and Subcellular Distribution of Costimulatory Molecules B7-H1,B7-H3 and B7-H4 in Human Hematologic Malignancy Cell Lines].
Zhang W; Wang J; Wang YF; Zhu MX; Wan WL; Li HS; Wu FF; Yan XX; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1539-1546. PubMed ID: 27784389
[TBL] [Abstract][Full Text] [Related]
12. Targeting bladder cancer using activated T cells armed with bispecific antibodies.
Ma J; Ge J; Xue X; Xiu W; Ma P; Sun X; Zhang M
Oncol Rep; 2018 Mar; 39(3):1245-1252. PubMed ID: 29328392
[TBL] [Abstract][Full Text] [Related]
13. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.
Han H; Ma J; Zhang K; Li W; Liu C; Zhang Y; Zhang G; Ma P; Wang L; Zhang G; Tao H; Gao B
Int J Oncol; 2014 Dec; 45(6):2446-54. PubMed ID: 25242665
[TBL] [Abstract][Full Text] [Related]
14. [Research Progress on Co-stimulating Molecule B7-H3 in Hematological Malignancies].
Zhang W; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1758-62. PubMed ID: 26708906
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
[TBL] [Abstract][Full Text] [Related]
16. B7-H3 on breast cancer cell MCF7 inhibits IFN-γ release from tumour-infiltrating T cells.
Shao L; Yu Q; Xia R; Zhang J; Gu S; Yu D; Zhuang Z
Pathol Res Pract; 2021 Aug; 224():153461. PubMed ID: 34265738
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of B7-H3 Expression During the Progression of Hepatitis B Virus Infection.
Gao F; Xu JC; Zhu L; Chen H; Zhu XY; You XR; Li SX; Zhu CL; Yang C; Zhu CW; Xu P
Viral Immunol; 2018 Dec; 31(10):668-675. PubMed ID: 30481143
[TBL] [Abstract][Full Text] [Related]
18. B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells.
Lu H; Shi T; Wang M; Li X; Gu Y; Zhang X; Zhang G; Chen W
Oncoimmunology; 2020; 9(1):1748991. PubMed ID: 32363121
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of costimulatory molecule B7-H3 expression on CD3(+) T cells in colorectal carcinoma.
Mao Y; Sun J; Wang WP; Zhang XG; Hua D
Chin Med J (Engl); 2013 Aug; 126(16):3035-8. PubMed ID: 23981607
[TBL] [Abstract][Full Text] [Related]
20. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
